Evidence map›Paper›PMID 35162436›Full record

ArticleInternational journal of environmental research and public health2022

Predicting Ovarian-Cancer Burden in Catalonia by 2030: An Age-Period-Cohort Modelling.

Paula Peremiquel-Trillas, Jon Frias-Gomez, Laia Alemany, Alberto Ameijide, Mireia Vilardell, Rafael Marcos-Gragera, Sònia Paytubi, Jordi Ponce, José Manuel Martínez, Marta Pineda and 8 more

Open access · goldAbstract read
In one paragraph

Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Quality of Life of Gynaeoncology Patients and Family Caregivers.International journal of environmental research and public health · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

Paula Peremiquel-TrillasCancer Epidemiology Research Programme, Catalan Institute of Oncology, Av. Gran Vía 199-203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
Jon Frias-GomezCancer Epidemiology Research Programme, Catalan Institute of Oncology, Av. Gran Vía 199-203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
Laia AlemanyCancer Epidemiology Research Programme, Catalan Institute of Oncology, Av. Gran Vía 199-203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
Alberto AmeijideTarragona Cancer Registry, Cancer Epidemiology and Prevention Service, Sant Joan de Reus University Hospital, Av. Dr. Josep Laporte 2, 43204 Reus, Spain.ORCID 0000-0002-9285-2627
Mireia VilardellIndependent Researcher, 08028 Barcelona, Spain.
Rafael Marcos-GrageraConsortium for Biomedical Research in Epidemiology and Public Health-CIBERESP, Carlos III Institute of Health, Av. De Monforte de Lemos 5, 28029 Madrid, Spain.ORCID 0000-0001-9824-3657
Sònia PaytubiCancer Epidemiology Research Programme, Catalan Institute of Oncology, Av. Gran Vía 199-203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.ORCID 0000-0002-5392-953X
Jordi PonceBellvitge Biomedical Research Institute-IDIBELL, Av. Gran Vía 199-203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.ORCID 0000-0002-0613-2261
José Manuel MartínezBellvitge Biomedical Research Institute-IDIBELL, Av. Gran Vía 199-203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.ORCID 0000-0002-8322-7694
Marta PinedaHereditary Cancer Programme, Catalan Institute of Oncology, Av. Gran Vía 199-203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.ORCID 0000-0002-5403-5845
Joan BrunetBellvitge Biomedical Research Institute-IDIBELL, Av. Gran Vía 199-203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.ORCID 0000-0003-1945-3512
Xavier Matías-GuiuBellvitge Biomedical Research Institute-IDIBELL, Av. Gran Vía 199-203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
Marià CarullaTarragona Cancer Registry, Cancer Epidemiology and Prevention Service, Sant Joan de Reus University Hospital, Av. Dr. Josep Laporte 2, 43204 Reus, Spain.
Jaume GalceranTarragona Cancer Registry, Cancer Epidemiology and Prevention Service, Sant Joan de Reus University Hospital, Av. Dr. Josep Laporte 2, 43204 Reus, Spain.
Ángel IzquierdoEpidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Catalan Institute of Oncology, Department of Health, Government of Catalonia, Av. França-Sant Ponç s/n, 17007 Girona, Spain.
Josep M BorràsBellvitge Biomedical Research Institute-IDIBELL, Av. Gran Vía 199-203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.ORCID 0000-0001-7330-6308
Laura CostasCancer Epidemiology Research Programme, Catalan Institute of Oncology, Av. Gran Vía 199-203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.ORCID 0000-0003-2755-302X
Ramon ClèriesBellvitge Biomedical Research Institute-IDIBELL, Av. Gran Vía 199-203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
Institut d'Investigació Biomédica de Bellvitge · ESGeneralitat de Catalunya · ESBellvitge University Hospital · ESInstitut de Recerca Biomèdica Catalunya Sud · ESInstitut Català d'Oncologia · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer is the most lethal gynaecological cancer in very-high-human-development-index regions. Ovarian cancer incidence and mortality rates are estimated to globally rise by 2035, although incidence and mortality rates depend on the region and prevalence of the associated risk factors. The aim of this study is to assess changes in incidence and mortality of ovarian cancer in Catalonia by 2030. Bayesian autoregressive age-period-cohort models were used to predict the burden of OC incidence and mortality rates for the 2015-2030 period. Incidence and mortality rates of ovarian cancer are expected to decline in Catalonia by 2030 in women ≥ 45 years of age. A decrease in ovarian-cancer risk was observed with increasing year of birth, with a rebound in women born in the 1980s. A decrease in mortality was observed for the period of diagnosis and period of death. Nevertheless, ovarian-cancer mortality remains higher among older women compared to other age groups. Our study summarizes the most plausible scenario for ovarian-cancer changes in terms of incidence and mortality in Catalonia by 2030, which may be of interest from a public health perspective for policy implementation.

Indexed as

Ovarian NeoplasmsAgedBayes TheoremCarcinoma, Ovarian EpithelialFemaleHumansIncidenceSpainburdenincidencemortalityovarian cancerprojectionssurvivaltime trends

Identifiers

PMID35162436
PMCPMC8834772
OpenAlexW4210276988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.